MedTrace Logo

Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions

NCT01399931 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2015-10-19

No results posted yet for this study

Summary

To assess specificity and overall accuracy of interim dual-point acquisition PET in predicting treatment outcome.

The study is aimed at assessing the specificity of interim dual-point PET performed after 2 ABVD cycles to predict treatment outcome in early-stage Hodgkin's Lymphoma patients presenting bulky lesions at baseline.

Conditions

  • Hodgkin's Lymphoma

Sponsors & Collaborators

  • Consorzio Mario Negri Sud

    collaborator OTHER

  • Fondazione Italiana Linfomi - ETS

    collaborator OTHER

  • Ospedale Santa Croce-Carle Cuneo

    lead OTHER

Principal Investigators

  • Andrea Gallamini, MD · Azienda Sanitaria Ospedaliera Santa Croce e Carle Cuneo

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-10-31
Completion
2017-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01399931 on ClinicalTrials.gov